Muhammad Nazmul Hasan, MS
PhD student, Department of Biochemistry,
Aichi Medical University, School of Medicine,
Nagakute, Aichi, Japan
Mr. Muhammad Nazmul Hasan holds his BSc and MS degrees from the Department of Biochemistry and Molecular Biology, University of Chittagong, Bangladesh. He is presently pursuing his Ph.D. on improving the efficiency of targeted knock-in mediated by CRISPR/Cas9 nickases under the supervision of Professor Dr. Hiroyuki Konishi in the Department of Biochemistry, Aichi Medical University, Japan.
Since January 2015, he started his research career in Laboratory of Eukaryotic Gene Expression and Function (EuGEF), BMB, CU, where he was involved in addressing the molecular mechanisms of arsenic-induced immune disorders, hyperkeratosis, and delay in wound healing and in search of their therapeutic targets. Along with other projects, he also investigated the interacting partners of different signaling molecules to justify therapeutic and diagnostic strategies targeting breast cancer and head & neck cancer.
Besides, he has also contributed significantly in development and production of several biosimilars and discovery of novel drugs in the R&D facility of Globe Biotech Limited, Dhaka, Bangladesh.
Outside the lab activities, he is interested in riding, driving, travelling, exploring the beauty of nature and listening music.
Karnan S, Ota A, Hideki M, Rahman ML, Hasan MN, Wahiduzzaman M, Hanamura I, Lam VQ, Inoko A, Hyodo T, Konishi H, Tsuzuki S, Hosokawa Y. Identification of CD24 as a potential diagnostic and therapeutic target for malignant pleural mesothelioma. Cell Death Discov. 6, 127 (2020). DOI: 10.1038/s41420-020-00364-1; PMID: 33298865; PMCID: PMC7674463
Noman ASM, Parag RR, Rashid MI, Islam S, Rahman MZ, Chowdhury AA, Sultana A, Jerin C, Siddiqua A, Rahman ML, Nayeem J, Akther S, Baidya S, Shil RK, Rahman M, Shirin A, Mahmud R, Hossain SMI, Sumi SA, Chowdhury A, Basher SB, Hasan A, Bithy S, Aklima J, Chowdhury N, Hasan MN, Banu T, Chowdhury S, Hossain MM, Yeger H, Farhat WA, Islam SS. Chemotherapeutic resistance of head and neck squamous cell carcinoma is mediated by EpCAM induction driven by IL-6/p62 associated Nrf2-antioxidant pathway activation. Cell Death Dis. 2020 Aug 20;11(8):663. DOI: 10.1038/s41419-020-02907-x. PMID: 32814771; PMCID: PMC7438524.